{
    "clinical_study": {
        "@rank": "16540", 
        "arm_group": {
            "arm_group_label": "Treatment (bortezomib, chemotherapy)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive bortezomib SC on days 1, 4, 8, and 11; doxorubicin hydrochloride IV on day 1; pegaspargase IV or IM on days 5 and 22; vincristine sulfate IV on days 1, 8, 15, and 22; dexamethasone PO daily on days 1-14; cytarabine IT on day 1 and methotrexate IT on day 15. Patients with central nervous system disease receive intrathecal treatment per investigator's discretion."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies how well giving bortezomib together with combination\n      chemotherapy works in treating patients with relapsed or refractory acute lymphoblastic\n      leukemia. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes\n      needed for cell growth. Drugs used in chemotherapy, such as doxorubicin hydrochloride,\n      vincristine sulfate, pegaspargase, dexamethasone, and cytarabine, work in different ways to\n      stop the growth of cancer cells, either by killing the cells or by stopping them from\n      dividing. Giving bortezomib together with combination chemotherapy may be an effective\n      treatment for acute lymphoblastic leukemia"
        }, 
        "brief_title": "Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia", 
        "condition": [
            "B-cell Adult Acute Lymphoblastic Leukemia", 
            "Ph Positive Adult Acute Lymphoblastic Leukemia", 
            "Recurrent Adult Acute Lymphoblastic Leukemia", 
            "T-cell Adult Acute Lymphoblastic Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Determine the response rate of bortezomib in combination with a chemotherapy backbone of\n      doxorubicin (doxorubicin hydrochloride), vincristine (vincristine sulfate), PEG-asparaginase\n      (pegaspargase), and dexamethasone in patients with relapsed/refractory acute lymphoblastic\n      leukemia.\n\n      SECONDARY OBJECTIVES:\n\n      I. Determine progression free survival. II. Estimate the rate of complete response (CR) and\n      CR with incomplete platelet recovery (CRp) after this re-induction compared to a historical\n      baseline.\n\n      III. Estimate failure-free survival (FFS) and survival percent at 1 year compared to a\n      historical baseline.\n\n      IV. Assess safety and tolerability of the study drug. V. Determine whether bortezomib\n      induces reactive oxygen species (ROS) in circulating acute lymphoblastic leukemia (ALL)\n      blast cells.\n\n      OUTLINE:\n\n      Patients receive bortezomib subcutaneously (SC) on days 1, 4, 8, and 11; doxorubicin\n      hydrochloride intravenously (IV) on day 1; pegaspargase IV or intramuscularly (IM) on days 5\n      and 22; vincristine sulfate IV on days 1, 8, 15, and 22; dexamethasone orally (PO) daily on\n      days 1-14; cytarabine intrathecally (IT) on day 1 and methotrexate intrathecally (IT) on day\n      15. Patients with central nervous system disease receive intrathecal treatment per\n      investigator's discretion.\n\n      After completion of study treatment, patients are followed up every 3 months for up to 2\n      years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Voluntary written informed consent before performance of any study-related procedure\n             not part of normal medical care, with the understanding that consent may be withdrawn\n             by the subject at any time without prejudice to future medical care\n\n          -  Female subjects who:\n\n               -  Are postmenopausal for at least 1 year before the screening visit, OR\n\n               -  Are surgically sterile, OR\n\n               -  If they are of childbearing potential, agree to practice 2 effective methods of\n                  contraception, at the same time, from the time of signing the informed consent\n                  form through 30 days after the last dose of bortezomib, or agree to completely\n                  abstain from heterosexual intercourse\n\n          -  Male subjects, even if surgically sterilized (i.e., status post vasectomy) who:\n\n               -  Agree to practice effective barrier contraception during the entire study\n                  treatment period and through a minimum of 30 days after the last dose of study\n                  drug, OR\n\n               -  Agree to completely abstain from heterosexual intercourse\n\n          -  \u2022 The patient has relapsed or refractory B or T cell acute lymphoblastic leukemia\n             that has progressed following at least one prior therapy. Ph+ patients are eligible.\n             Relapsed ALL is defined in patients as the reappearance of leukemia cells in the\n             peripheral blood or bone marrow or appearance of extramedullary disease after a\n             complete remission. Refractory ALL is defined in patients as failure to achieve a\n             complete remission after induction therapy. Complete remission is defined by <5%\n             leukemia cells in the bone marrow with recovery of peripheral blood counts. Relapsed\n             disease can be documented by bone marrow biopsy (>5% cells in the bone marrow) or by\n             flow cytometry in the peripheral blood or biopsy of extramedullary disease.\n\n          -  Must have received at least one (1) line of prior systemic therapy that may NOT have\n             included VELCADE (bortezomib); patients who have undergone autologous/allogeneic stem\n             cell transplantation are eligible\n\n          -  Transplant eligible patients are eligible\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n\n          -  No poorly controlled intercurrent illness including, but not limited to, ongoing or\n             active infection, poorly controlled diabetes, symptomatic congestive heart failure,\n             or psychiatric illness that in the opinion of the investigator would limit compliance\n             with study requirements\n\n          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper\n             limit of normal\n\n          -  Total bilirubin =< 1.5 x upper limit of normal (ULN) unless elevation is deemed due\n             to leukemia infiltration. In these patients, dose modifications may be required based\n             on standard guidelines.\n\n          -  Patients must have adequate renal function defined as creatinine clearance of >= 30\n             ml/minute (Cockcroft-Gault)\n\n        Exclusion Criteria:\n\n          -  Patient has > 1.5 x ULN total bilirubin\n\n          -  Patient has >= grade 2 peripheral neuropathy\n\n          -  Patient had myocardial infarction within 6 months prior to enrollment or has New York\n             Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe\n             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute\n             ischemia or active conduction system abnormalities; prior to study entry, any\n             electrocardiogram (ECG) abnormality at screening must be documented by the\n             investigator as not medically relevant\n\n          -  Patient has hypersensitivity to bortezomib, boron, or mannitol\n\n          -  Female subject is pregnant or lactating\n\n          -  Serious medical or psychiatric illness likely to interfere with participation in this\n             clinical study\n\n          -  Diagnosed or treated for another malignancy within 2 years of enrollment, with the\n             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of\n             the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy\n\n          -  Participation in clinical trials with other investigational agents not included in\n             this trial throughout the duration of this trial\n\n          -  Radiation therapy within 3 weeks before randomization; enrollment of subjects who\n             require concurrent radiotherapy (which must be localized in its field size) should be\n             deferred until the radiotherapy is completed and 3 weeks have elapsed since the last\n             date of therapy\n\n          -  The patient has been exposed to >= 350mg/m^2 of anthracycline (doxorubicin\n             equivalent)\n\n          -  The patient has a left ventricular ejection fraction of < 40%"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "17", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01769209", 
            "org_study_id": "HEMALL0008", 
            "secondary_id": "NCI-2012-03094"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (bortezomib, chemotherapy)", 
                "description": "Given SC", 
                "intervention_name": "bortezomib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "LDP 341", 
                    "MLN341", 
                    "VELCADE"
                ]
            }, 
            {
                "arm_group_label": "Treatment (bortezomib, chemotherapy)", 
                "description": "Given IV", 
                "intervention_name": "doxorubicin hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ADM", 
                    "ADR", 
                    "Adria", 
                    "Adriamycin PFS", 
                    "Adriamycin RDF"
                ]
            }, 
            {
                "arm_group_label": "Treatment (bortezomib, chemotherapy)", 
                "description": "Given IV or IM", 
                "intervention_name": "pegaspargase", 
                "intervention_type": "Drug", 
                "other_name": [
                    "L-asparaginase with polyethylene glycol", 
                    "Oncaspar", 
                    "PEG-ASP", 
                    "PEG-L-asparaginase"
                ]
            }, 
            {
                "arm_group_label": "Treatment (bortezomib, chemotherapy)", 
                "description": "Given IV", 
                "intervention_name": "vincristine sulfate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "leurocristine sulfate", 
                    "VCR", 
                    "Vincasar PFS"
                ]
            }, 
            {
                "arm_group_label": "Treatment (bortezomib, chemotherapy)", 
                "description": "Given PO", 
                "intervention_name": "dexamethasone", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Aeroseb-Dex", 
                    "Decaderm", 
                    "Decadron", 
                    "DM", 
                    "DXM"
                ]
            }, 
            {
                "arm_group_label": "Treatment (bortezomib, chemotherapy)", 
                "description": "Given IT", 
                "intervention_name": "cytarabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ARA-C", 
                    "arabinofuranosylcytosine", 
                    "arabinosylcytosine", 
                    "Cytosar-U", 
                    "cytosine arabinoside"
                ]
            }, 
            {
                "arm_group_label": "Treatment (bortezomib, chemotherapy)", 
                "description": "Given IT", 
                "intervention_name": "methotrexate", 
                "intervention_type": "Drug", 
                "other_name": "MTX; amethopterin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pegaspargase", 
                "Bortezomib", 
                "Asparaginase", 
                "Cytarabine", 
                "Dexamethasone", 
                "Doxorubicin", 
                "Methotrexate", 
                "Vincristine", 
                "Dexamethasone acetate", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 15, 2013", 
        "location": {
            "contact": {
                "email": "mliedtke@stanford.edu", 
                "last_name": "Michaela Liedtke", 
                "phone": "650-498-7061"
            }, 
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford University"
            }, 
            "investigator": {
                "last_name": "Michaela Liedtke", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Subcutaneous Bortezomib in Combination With Chemotherapy in Relapsed/Refractory Adult Acute Lymphoblastic Leukemia", 
        "overall_official": {
            "affiliation": "Stanford University", 
            "last_name": "Michaela Liedtke", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Response rates will be evaluated and accompanied by 95% confidence intervals using the binomial distribution. Response rate by categories will be calculated with 95% confidence intervals.", 
            "measure": "CR rate", 
            "safety_issue": "No", 
            "time_frame": "On day 29 at the end of induction therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01769209"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Stanford University", 
            "investigator_full_name": "Michaela Liedtke", 
            "investigator_title": "Assistant Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Analyzed using Kaplan-Meier survival analysis and accompanied with 95% confidence interval.", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "From the start of treatment to disease progression or death, whichever comes first, assessed up to 2 years"
            }, 
            {
                "description": "Compared to a historical baseline.", 
                "measure": "CR and CRp rate after re-induction", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Analyzed by the Kaplan Meier method. Compared to a historical baseline.", 
                "measure": "Failure-free survival (FFS)", 
                "safety_issue": "No", 
                "time_frame": "At 1 year"
            }, 
            {
                "description": "Compared to a historical baseline.", 
                "measure": "Survival percent", 
                "safety_issue": "No", 
                "time_frame": "At 1 year"
            }, 
            {
                "description": "Toxicity profile will be presented by rate of overall toxicity and rates of grade 3 or 4 toxicities analyzed separately and combined. Adverse events will be summarized and accompanied by 95% confidence intervals using binomial distribution.", 
                "measure": "Incidence of adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 45 days after completion of treatment"
            }
        ], 
        "source": "Stanford University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}